Suicidality, violence and mania caused by selective serotonin reuptake inhibitors (SSRIs): A review and analysis

International Journal of Risk and Safety in Medicine

Volumn 16, Issue 1, 2003, Pages 31-49

  Breggin, Peter R ^a  

^a NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CITALOPRAM; CLOMIPRAMINE; ESCITALOPRAM; FLUOXETINE; FLUVOXAMINE; NEFAZODONE; PAROXETINE; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; VENLAFAXINE;

AGITATED DEPRESSION; AGITATION; AKATHISIA; AMNESIA; ANXIETY DISORDER; CLINICAL TRIAL; CONFUSION; CRIMINAL LAW; DRUG WITHDRAWAL; HEART PALPITATION; HUMAN; HYPOMANIA; INSOMNIA; MALPRACTICE; MANIA; MANIC DEPRESSIVE PSYCHOSIS; NERVOUSNESS; REVIEW; SUICIDAL BEHAVIOR; SWEATING; TREMOR; VIOLENCE;

EID: 0345258071     PISSN: 09246479     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (80)

1. American Psychiatric Association, Practice Guidelines for Major Depressive Disorder in Adults, American Psychiatric Association, Washington, DC, 1993. Also published in the American Journal of Psychiatry (April) (1993)
2. American Psychiatric Association, Practice Guidelines for Major Depressive Disorder in Adults, American Psychiatric Association, Washington, DC, 1993. Also published in the American Journal of Psychiatry (April) (1993)
3. American Psychiatric Association, Diagnostic and Statistical Manual of Mental Disorders, Fourth edition (DSM-IV), American Psychiatric Association, Washington, DC, 1994.
4. American Psychiatric Association, Diagnostic and Statistical Manual of Mental Disorders, Fourth edition, Text Revision (DSM-IV-TR), American Psychiatric Association, Washington, DC, 2000.
5. J. Bastani, M. Troester and A. Bastani, Serotonin syndrome and fluvoxamine: A case study, Nebraska Medical Journal 81 (1996), 107-109.
6. C. Beasley, Activation and sedation in fluoxetine clinical studies. Unpublished in-house document generated by Eli Lilly and Company during the FDA-approval process of Prozac for depression and obtained during discovery for Fentress v. Shay Communications et al., Fentress Trial Exhibit 70, 1988.
7. S. Borg and K. Brodin, Antidepressant drugs, in: Meyler's Side Effects of Drugs, Thirteenth edition, M.N.G. Dukes, ed., Elsevier, New York, 1996, pp. 31-80.
8. R. Bost and P. Kemp, A possible association between fluoxetine use and suicide, Journal of Analytic Toxicology 16 (1992), 142-145.
9. P. Breggin, A case of fluoxetine-induced stimulant side effects with suicidal ideation associated with a possible withdrawal reaction ("crashing"). International Journal of Risk & Safety in Medicine 3 (1992), 325-328.
10. P. Breggin, Testimony in Joyce Fentress et al. vs. Shea Communications et al. [The Wesbecker Case]. Jefferson Circuit Court, Division, 1, Louisville, Kentucky, No. 90-CI-06033, Volume XVI, 1994.
11. P. Breggin, Brain-Disabling Treatments in Psychiatry: Drugs, Electroshock, and the Role of the FDA, Springer, New York, 1997.
12. P. Breggin, Analysis of adverse behavioral effects of benzodiazepines with a discussion of drawing scientific conclusions from the FDA's Spontaneous Reporting System, Journal of Mind and Behavior 19 (1998), 21-50.
13. P. Breggin, The Antidepressant Fact Book, Perseus Books, Cambridge, MA, 2001.
14. P. Breggin, Fluvoxamine as a cause of stimulation, mania, and aggression with a critical analysis of the FDA-approved label, International Journal of Risk & Safety in Medicine 14 (2002), 71-86.
15. P. Breggin and G. Breggin, Talking Back to Prozac: What Doctors Aren't Telling You About Today's Most Controversial Drug, St. Martin's Press, New York, 1994.
16. P. Breggin and D. Cohen, Your Drug May be Your Problem: How and Why to Stop Taking Psychiatric Medications, Perseus Books, Cambridge, MA, 1999.
17. British Medical Association and Royal Pharmaceutical Society of Great Britain, British National Formulary (BNF), the Pharmaceutical Press, London, England, 1991.
18. C. Burrai, A. Bocchetta and M. Zompo, Mania and-fluvoxamine, American Journal of Psychiatry 148 (1991), 1263-1264.
19. R. Christen, Paroxetine-induced mania, American Journal of Psychiatry 152 (1995), 1439-1500.
20. J. Constantino, M. Liberman and M. Kincaid, Effects of serotonin reuptake inhibitors on aggressive behavior in psychiatric hospitalized adolescents: Results of an open trial, Journal of Child and Adolescent Psychopharmacology 7 (1997), 31-44.
21. W Creaney, I. Murray and D. Healy, Antidepressant induced suicidal ideation, Human Psychopharmacology 6 (1991), 329-332.
22. K. Dasgupta, Additional cases of suicidal ideation associated with fluoxetine, American Journal of Psychiatry 147 (1990), 1570.
23. S. Donovan, A. Clayton, M. Beeharry S. Jones, C. Kirk, K. Waters, D. Gardner, J. Faulding and R. Madeley, Deliberate self-harm-and antidepressant drugs: Investigation-of a possible link, British Journal of Psychiatry 177(2000), 551-556.
24. S. Donovan, M. Kelleher, J. Lambourn and T. Foster, The occurrence of suicide following the prescription of antidepressant drugs, Archives of Suicide Research 5 (1999), 181-192.
25. A. Dorevitch, Y. Frankel, A. Bar-Halperin, R. Aronzon and Zilberman, Fluvoxamine-associated manic behavior: A case series, Annals of Pharmacotherapy 27 (1993), 1455-1457.
26. Drug Facts and Comparisons, Facts and Comparisons, St. Louis, 2003.
27. D. Ebert, R. Albert, A. May, A. Merz, H. Murata, I. Stosiek and B. Zahner, The serotonin syndrome and psychosis-like side effects of fluvoxamine in clinical use - An estimation of incidence, European Neuro-Pharmacology 7 (1997), 71-74.
28. G.J. Emslie, A.J. Rush, W.A. Weinberg, R.A. Kowatch, C.W. Hughes, T. Carmody and J. Rintelmann, A double-blind, randomized, placebo-controlled trial of fluoxetine in children and adolescents with depression, Archives of General Psychiatry 54 (1997), 1031-1037.
29. Fentress et al. vs. Shea Communications et al. [The Wesbecker Case]. Jefferson Circuit Court, Division, 1, Louisville, Kentucky, No. 90-CI-06033, Volume XVI, 1994.
30. S. Fisher, T. Kent and S. Bryant, Postmarketing surveillance by patient self-monitoring: Preliminary data for sertraline versus fluoxetine, Journal of Clinical Psychiatry 56 (1995), 288-296.
31. S. Fisher, S. Bryant and T. Kent, Postmarketing surveillance by patient self-monitoring: Trazodone versus fluoxetine, Journal of Clinical Psychopharmacology 13 (1993), 235-242.
32. Food and Drug Administration (FDA), Transcript of Psychopharmacologic Drugs Advisory Committee: 34th Meeting, Department of Health and Human Services, Public Health Service, Food and Drug Administration, Rockville, MD, Obtained through Freedom of Information Act, 1991.
33. Food and Drug Administration (FDA), Adverse Event Reporting System (AERS): Freedom of Information (FOI) Report, Center for Drug Evaluation and Research, Food and Drug Administration, Rockville, MD, Obtained through Freedom of Information Act, 1999.
34. D. Frankenfield, S. Baker, W. Lange, Y. Caplan and J. Smialek, Fluoxetine and violent death in Maryland, Forensic Science International 64 (1994), 107-117.
35. O. Fumihiko and K. Okajima, Violent acts associated with fluvoxamine treatment, Journal of Psychiatry and Neuroscience 26 (2001), 339-349.
36. J. Glenmullen, Prozac Backlash, Simon & Schuster, New York, 2000.
37. J. Gorman, M. Liebowitz, A. Fyer, D. Goetz, R. Campeas, M. Fyer, S. Davies and D. Klein, An open trial of fluoxetine in the treatment of panic disorder, Journal of Clinical Psychopharmacology 7 (1987), 329-332.
38. S. Grimsley and M. Jann, Paroxetine, sertraline, and fluvoxamine: New selective serotonin reuptake inhibitors, Clinical Pharmacy 11 (1992), 930-957.
39. C. Gualtieri, Paradoxical effects of fluoxetine, Journal of Clinical Psychopharmacology 11 (1991), 393-394.
40. D. Healy, Lines of evidence on the risks of suicide with selective serotonin reuptake inhibitors, Psychotherapy and Psychosomatics 72 (2003), 71-79.
41. D. Healy, Emergency of antidepressant induced suicidality, Primary Care Psychiatry 2000 6 (2000), 23-28.
42. D. Healy, The fluoxetine and suicide controversy: A review of the evidence, CNS Drugs 1 (1994), 223-231.
43. R. Hoehn-Saric, J. Lipsey and D. McLeod, Apathy and indifference in patients on fluvoxamine and fluoxetine, Journal of Clinical Psychopharmacology 10 (1990), 343-345.
44. C. Hoover, Additional cases of suicidal ideation associated with fluoxetine, American Journal of Psychiatry 147 (1990), 1569-1570.
45. R. Howland, Induction of mania with serotonin reuptake inhibitors, Journal of Clinical Psychopharmacology 16 (1996), 425-427.
46. J. Jain, B. Birmaher, M. Garcia, M. Al-Shabbout and N. Ryan, Fluoxetine in children and adolescents with mood disorders: A chart review of efficacy and adverse reactions, Journal of Child and Adolescent Psychopharmacology 2 (1992), 259-265.
47. S. Jick, A. Dean and H. Jick, Antidepressants and suicide, British Medical Journal 310 (1995), 215-218.
48. R. Kapit, Safety Review of NDA 18-936 [Prozac]. Internal document of the Department of Health and Human Services, Public Health Service, Food and Drug Administration, Center for Drug Evaluation and Research. Obtained through the Freedom of Information Act, 1986.
49. R. Kapit, Response to Dr. Laughren's Q's regarding Review of Safety Update, Memo #3." NDA 18-936. Internal document of the Department of Health and Human Services, Public Health Service, Food and Drug Administration, Center for Drug Evaluation and Research. Obtained through the Freedom of Information Act, 1986.
50. A. Khan, S. Khan, R. Leventhal and W. Brown, Symptom reduction and suicide risk in patients treated with placebo in antidepressant clinical trials: a replication analysis of the Food and Drug Administration database, International Journal of Neuropsychopharmacology 4 (2001), 113-118.
51. A. Khan, H. Warner and W. Brown, Symptom reduction and suicide risk in patients treated with placebo in antidepressant clinical trials: An analysis of the Food and Drug Administration database, Archives of General Psychiatry 57 (2000), 311-317.
52. R. King, M. Riddle, P. Chappell, M. Hardin, G. Anderson, P. Lombroso and L. Scahill, Emergence of self-destructive phenomena in children and adolescents during fluoxetine treatment, Journal of the American Academy of Child and Adolescent Psychiatry 30 (1991), 179-186.
53. J. Koizumi, Fluoxetine and suicidal ideation, Journal of the American Academy of Child and Adolescent Psychiatry 30 (1991), 695.
54. The Lancet, Editorials: 5-HT blockers and all that, 336 (1990), 345-346.
55. R. Lane, SSRI-induced extrapyramidal side-effects and akathisia: Implications for treatment, Journal of Psychopharmacology 12 (1998), 192-214.
56. B. Leonard, Pharmacological differences of serotonin reuptake inhibitors and possible clinical relevance, Drugs 43(Supplement 2) (1992), 3-10.
57. L. Levine, S. Rosenblatt and J. Bosomworth, Use of a serotonin re-uptake inhibitor, fluoxetine, in the treatment of obesity, International Journal of Obesity 11(supplement 3) (1987), 185-190.
58. J. Lipinski, Jr., G. Mallaya, P. Zimmerman and H. Pope, Jr., Fluoxetine-induced akathisia: clinical and theoretical implications, Journal of Clinical Psychiatry 50 (1989), 339-352.
59. L. Marangell, S. Yudofsky and J. Silver, Psychopharmacology and electroconvulsive therapy, in: The American Psychiatric Press Textbook of Psychiatry, R. Hales, S. Yudofsky and J. Talbott, eds, Chapter 27, American Psychiatric Press, Washington, DC, 1999, pp. 1025-1132.
60. P. Masand, S. Gupta and M. Dewan, Suicidal ideation related to fluoxetine treatment, New England Journal of Medicine 324 (1991), 420.
61. M. Muijen, D. Roy, T. Silverstone, A. Mehmet and M. Thristie, A comparative clinical trial of fluoxetine, mianserin and placebo in depressed outpatients, Acta Psychiatrica Scandinavica 78 (1988), 384-390.
62. F. Okada and K. Okajima, Violent acts associated with fluvoxamine treatment, Journal of Psychiatry & Neuroscience 26 (2001), 339-340.
63. J. Oldroyd, Paroxetine-induced mania, Journal of the American Academy of Child and Adolescent Psychiatry 36 (1997), 721-722.
64. R. Peyre, H. Verdous and M. Bourgeois, Fluvoxamine: Study of treatment effect on a group of 189 hospitalized patients with depression, (French), Encephale 18(1) (1992), 73-74 (in French).
65. Physicians' Desk Reference, Medical Economics, Montvale, NJ, 2001.
66. Physicians' Desk Reference, Medical Economics, Montvale, NJ, 2003.
67. A. Preda, R. MacLean, C. Mazure and M. Bowers, Antidepressant-associated mania and psychosis resulting in psychiatric admission, Journal of Clinical Psychiatry 62 (2001), 30-33.
68. Public Citizen Health Research Group, Re: Citizens Petition for revision of fluoxetine (Prozac) labeling. Letter to David Kessler, Commissioner of the Food and Drug Administration, Public Citizen, Washington, DC, 1991.
69. M. Riddle, R. King, M. Hardin, L. Scahill, S. Ort, P. Chappell, A. Rasmusson and J. Leckman, Behavioral side effects of fluoxetine in children and adolescents, Journal of Child and Adolescent Psychopharmacology 1 (1990/1991), 193-198.
70. A. Rothschild and C. Locke, Reexposure to fluoxetine after serious suicide attempts by three patients: The role of akathisia, Journal of Clinical Psychiatry 52 (1991), 491-493.
71. F. Sim, A single dose of fluvoxamine associated with an acute psychotic reaction, Canadian Journal of Psychiatry 45 (2000), 762.
72. M. Teicher, C. Glod and J. Cole, Emergence of intense suicidal preoccupations during fluoxetine treatment, American Journal of Psychiatry 147 (1990), 207-210.
73. M. Teicher, C. Glod and J. Cole, Antidepressant drugs and the emergence of suicidal tendencies, Drug Safety 8 (1993), 182-212.
74. A. Troisi, E. Vicario, F. Nuccetelli, N. Ciani and A. Pasini, Effects of fluoxetine on aggressive behavior in adult inpatients with mental retardation and epilepsy, Pharmacopsychiatry 28 (1995), 73-76.
75. T. Van Putten, Why do schizophrenic patients refuse-to take their drugs? Archives of General Psychiatry 31 (1974), 67-72.
76. T. Van Putten, The many faces of akathisia, Comprehensive Psychiatry, International Journal of Neuropsychopharmacology 2 (1975), 165-172.
77. D. Wilkinson, Loss of anxiety and increased aggression-in a 15-year-old boy taking fluoxetine, Journal of Psychopharmacology 13 (1999), 420.
78. W. Wirshing, T. Van Putten, J. Rosenberg, S. Marder, D. Ames and T. Hicks-Gray, Fluoxetine, akathisia, and suicidality: Is there a connection? Archives of General Psychiatry 49 (1992), 580-581.
79. Food and Drug Administration (FDA), FDA statement regarding the anti-depressant Paxil for pediatric population (June 19, 2003). www.fda.gov/eder/drug/infopage/paxil/default.htm.
80. Wyeth Pharmaceuticals, Dear Health Care Professional, August 22, 2003.